Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | |||
| Nexavar | Sorafenib | Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) | Do not reimburse | Complete | ||
| Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Neoadjuvant Breast Cancer | Do not reimburse | Complete | ||
| Stivarga Resubmission (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Constella | Linaclotide | Irritable bowel syndrome with constipation | Do not list | Complete | ||
| Dymista | Azelastine HCl and fluticasone propionate | Seasonal allergic rhinitis | Do not list | Complete | ||
| Cosentyx | Secukinumab | Plaque psoriasis | List with criteria/condition | Complete | ||
| Holkira Pak | Ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Istodax | Romidepsin | Peripheral T-Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Avastin | Bevacizumab | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 20, 2024